G

ood morning, everyone, and how are you today? We are just fine, thank you, especially since we are poised to enjoy an extended holiday break, during which time we hope to hang with our short people and observe important rituals. We hope that those of you on this side of the pond are doing the same. Have a wonderful time and, for everyone else, well, you will survive. To help speed things along, meanwhile, here are some tidbits. We hope you have a smashing few days and look forward to seeing you soon …

The Food and Drug Administration approved the first two-drug regimen to treat HIV, Reuters writes. The treatment, called Juluca, is a fixed-dose tablet combining two previously approved drugs, ViiV Healthcare’s dolutegravir and Johnson & Johnson’s rilpivirine. ViiV is majority-owned by GlaxoSmithKline (GSK), and the approval puts Glaxo ahead of Gilead Sciences (GILD) in the race to market with two-drug combinations for HIV treatments.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.